Why Is Caribou Biosciences ($CRBU) Stock Down -49.12% Today? (Find out why any stock moved today on Tickeron.) Massive decline: Shares of CRBU plunged roughly 49% on Wednesday, trading near $0.58 versus a prior close of $1.14. Primary catalyst: The company announced it is discontinuing its two allogeneic CAR-T cell therapy programs, vispa-cel and CB-011. Strategic review: The board authorized a process to explore strategic alternatives, including a possible merger, acquisition, or asset sale, with Wedbush Securities as financial advisor. Cost restructuring: A substantial workforce reduction is expected to be mostly completed by the fourth quarter of 2026. $EDIT $SANA $CRSP $SLDB
published
Why Is Caribou Biosciences ($CRBU) Stock Down -49.12% Today? (Find out why any stock moved today on Tickeron.) Massive decline: Shares of CRBU plunged roughly 49% on Wednesday, trading near $0.58 versus a prior close of $1.14. Primary catalyst: The company ann
$CRBU$EDIT$SANA$CRSP$SLDB
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.